Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Medline’s Backers Blackstone, Carlyle and Hellman & Friedman Raise $2.1 Billion Selling 60 Million Shares at $35.50, With a $200 Million Company Buyback, After the Stock Fell 3.8%

by Team Lumida
November 18, 2026
in Equities
Reading Time: 3 mins read
A A
0
Dow Ends the Week Down 2% for a Third Straight Loss While the Nasdaq Gains 0.3% and the 10-Year Returns to 5.00%
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Medline shareholders including Blackstone, Carlyle, Hellman & Friedman, the Abu Dhabi Investment Authority and GIC raised $2.1 billion in a share sale, Bloomberg reported, citing a company statement on Wednesday. The sellers sold 60 million shares at $35.50 apiece.
  • Medline will not receive any proceeds from the offering. The selling stockholders granted underwriters an option to buy up to an additional 9 million shares.
  • The company has agreed to buy back up to $200 million of its shares as part of the deal. Goldman Sachs, Morgan Stanley, Bank of America and JPMorgan were global coordinators and joint bookrunners.
  • Shares of Medline fell 3.8% on Tuesday, before the pricing was announced. The sale gives the private-equity backers a way to cut their holdings in a US-listed company in a market where the AI trade has been under pressure.

What Happened?

A group of Medline’s private-equity and sovereign-wealth backers sold 60 million shares at $35.50 each, raising $2.1 billion, according to a statement cited by Bloomberg. Medline itself will not receive proceeds but plans to repurchase up to $200 million of its stock. Underwriters hold an option on up to 9 million more shares.

Why It Matters?

Secondary sales by sponsors after an IPO are a common way for large holders to reduce their stake, and the pricing shows how much demand exists for the stock after Tuesday’s 3.8% decline. The company’s buyback offsets part of the supply.

What’s Next?

Watch how Medline trades relative to the $35.50 offer price once the sale settles, whether underwriters exercise the 9 million share option, and whether the sponsors return with further sales as lock-ups and market conditions allow. The pace of such follow-on offerings will indicate how receptive investors are to large block sales while tech valuations remain unsettled.

Affected Tickers and Coins: MDLN, BX, CG, GS, MS, BAC, JPM

Source: Bloomberg

Previous Post

Wall Street Expects Global Earnings Growth to Halve to 16% in 2027 From 33.5%, With Goldman Seeing US Profit Growth Falling From 36% to 11% as AI Capex Growth Peaks in the First Half

Next Post

US Judge Clears MIT-Educated Brothers of $25 Million Ethereum Fraud, Ruling the Network Has “No Terms of Use” in the Government’s First Criminal MEV Case

Recommended For You

The SEC Is Investigating Nvidia Over Whether Its Disclosures Misled Investors, the Same Day It Reports $115.8 Billion in Revenue and Huang Says He Would Return as CEO if Asked

by Team Lumida
13 minutes ago

WSJ reports the SEC is investigating Nvidia, including whether disclosures misled investors, as the company posts $115.8 billion in quarterly revenue.

Read more

Nvidia Posts $115.84 Billion Revenue and Guides to $130 Billion, Lifts Fiscal 2028 Growth Target to 75% and Adds $150 Billion to Buybacks, With Shares Up Almost 5% After Hours as the Board Rules Out Huang’s Return

by Team Lumida
21 minutes ago

Nvidia beat on revenue, guided Q4 to $130 billion and raised its fiscal 2028 growth target to 75%, with shares up almost 5% after hours.

Read more

JPMorgan Names Bregje de Best as Its Next CFO, With Jeremy Barnum Moving to Vice Chairman and Staying Through Early 2028

by Team Lumida
16 hours ago
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan plans to name Bregje de Best CFO after first-quarter results, with Jeremy Barnum becoming vice chairman through early 2028.

Read more

‘Big Short’ Investor Steve Eisman Says AI Neoclouds Are in ‘Big Trouble’ as Nvidia’s ‘Virtual Vertical Holding Company’ Unwinds

by Team Lumida
16 hours ago

Steve Eisman said AI neocloud stocks face the biggest fallout from the Nvidia scandal and favored hyperscalers if data center building slows.

Read more

Jensen Huang Will Testify Before Three House Committees on Dec. 1, as Nvidia Creates a Board Committee to Oversee Export Controls and National Security

by Team Lumida
16 hours ago

Former Nvidia CEO Jensen Huang will appear before three House panels Dec. 1 as Nvidia formed a board committee on export controls.

Read more

Options Price a 7% Nvidia Earnings Move, the Biggest Since February 2025, as the Stock Sits 35% Below Its October High and Morgan Stanley Calls It the Most Under-Owned Large-Cap Tech Name

by Team Lumida
16 hours ago

Options traders priced a 7% Nvidia earnings move, the biggest since early 2025, with shares down 35% from their October high and widely under-owned.

Read more

Nike Reaffirms Fiscal 2027 Guidance and Targets $3.00-$3.50 EPS and 12%-14% Margins by 2031 at Its First Investor Day in Nine Years

by Team Lumida
16 hours ago

Nike reaffirmed its fiscal 2027 outlook and set 2031 targets of $3.00 to $3.50 adjusted EPS and 12% to 14% operating margins at its investor day.

Read more

Disney Beats With $1.77 Adjusted EPS on $25.95 Billion Revenue, Targets $3 Billion of Savings by 2029 and Lifts Its Dividend 33% to $2

by Team Lumida
16 hours ago

Disney beat fiscal Q4 estimates, targeted $3 billion in cost savings by fiscal 2029 and raised its annual dividend 33% to $2 a share.

Read more

Home Depot Names CFO Richard McPhail CEO as Ted Decker Steps Down, While Q3 Comps Rise 2.2% but a Soft Holiday Outlook Sends Shares Lower

by Team Lumida
16 hours ago

Home Depot named CFO Richard McPhail CEO and beat Q3 estimates, but a cautious full-year outlook implied fourth-quarter EPS below consensus.

Read more

Anthropic Is Likely to Price Its IPO Above the $70-$78 Range as Books Close, With Nasdaq Trading Under ‘ANT’ Set for Nov. 19

by Team Lumida
16 hours ago

Anthropic is likely to price its IPO above the $70 to $78 range, sources told CNBC, ahead of its Nasdaq debut under the ticker ANT on Nov. 19.

Read more
Next Post

US Judge Clears MIT-Educated Brothers of $25 Million Ethereum Fraud, Ruling the Network Has "No Terms of Use" in the Government’s First Criminal MEV Case

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China’s Bold Economic Moves: What You Need to Know Now

China’s Property Slump Enters Fifth Year, Threatening Banks, Growth and Deflation Fight

November 24, 2025
Bitcoin Approaches $64K Amid Memecoin Frenzy

Bitcoin Approaches $64K Amid Memecoin Frenzy

October 7, 2024
SEC Advances Crypto ETFs Toward Mainstream with Key Rule Changes

SEC Advances Crypto ETFs Toward Mainstream with Key Rule Changes

July 30, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018